Safety of tiotropium in patients with asthma

Therapeutic Advances in Respiratory Disease
Daniel Dusser, Francine M Ducharme

Abstract

Given the high proportion of patients with asthma who remain uncontrolled despite controller treatment, there remains a need for the development of more effective treatment options with a proven safety and tolerability profile. Recently, asthma guidelines have evolved to incorporate new therapies, including long-acting muscarinic antagonists (LAMAs) and biologics. Here we focus on the safety profile of tiotropium, a LAMA, using data from the large-scale UniTinA-asthma® clinical trial program, which investigated the use of tiotropium in over 6000 patients with asthma who remained symptomatic despite receiving inhaled corticosteroids (ICS) maintenance therapy, with or without other adjunct therapies. The large number of patients included allows robust analysis of safety and tolerability. Overall, a similar incidence of patients reporting any adverse event (AE) was observed in the tiotropium (5 µg and 2.5 µg) and placebo groups. Asthma worsening, decreased peak expiratory flow, and upper respiratory tract infections were the most frequently reported AEs. Serious AEs (SAEs) and investigator-defined drug-related AEs were infrequently reported across all treatment groups, including the placebo group, and there were no deaths in any s...Continue Reading

References

Mar 24, 2007·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Jordana K SchmierGregory B Diette
Jul 14, 2009·Chest·Bartolome CelliDonald P Tashkin
Aug 3, 2011·The Journal of Allergy and Clinical Immunology·Eric D BatemanLeonardo M Fabbri
Sep 4, 2012·The New England Journal of Medicine·Huib A M KerstjensEric D Bateman
Mar 4, 2014·Therapeutic Advances in Chronic Disease·Khuder AlaghaPascal Chanez
Nov 14, 2015·The Journal of Allergy and Clinical Immunology. in Practice·Pierluigi PaggiaroEmilio Pizzichini
Mar 11, 2016·The Journal of Allergy and Clinical Immunology·Eckard HamelmannAttilio L Boner
Nov 5, 2016·The European Respiratory Journal·Eckard HamelmannAttilio L Boner
Feb 13, 2017·The Journal of Allergy and Clinical Immunology·Stanley J SzeflerEckard Hamelmann
Jul 12, 2017·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Gustavo J Rodrigo, Hugo Neffen
Jan 26, 2018·Drugs·Eckard Hamelmann, Stanley J Szefler
May 12, 2018·The Journal of Allergy and Clinical Immunology. in Practice·Christian VogelbergEckard Hamelmann

❮ Previous
Next ❯

Citations

Jul 21, 2020·Expert Opinion on Pharmacotherapy·Timothy E AlbertsonSusan Murin
Mar 5, 2020·Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia·Marcia Margaret Menezes PizzichiniAlberto Cukier
Dec 5, 2019·The New England Journal of Medicine·Sandra C Christiansen, Bruce L Zuraw
Sep 9, 2020·Postgraduate Medicine·Alan Kaplan, Ku-Lang Chang
Dec 10, 2020·Clinical and Molecular Allergy : CMA·Federica GaniGianenrico Senna
Feb 11, 2021·European Journal of Internal Medicine·Alberto PapiDave Singh

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00772538
NCT00776984
NCT01172808
NCT01172821
NCT01316380
NCT01340209
NCT01277523
NCT01257230
NCT01634152
NCT01634139

Software Mentioned

UniTinA
UPLIFT

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.